L Kuusalo1, D T Felson2, N Wang3, C E Lewis4, J Torner5, M C Nevitt6, T Neogi7. 1. Centre for Rheumatology and Clinical Immunology, Division of Medicine, University of Turku and Turku University Hospital, Turku, Finland. Electronic address: laura.kuusalo@utu.fi. 2. Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; University of Manchester and Central Manchester Foundation Trust, Manchester, UK. 3. Boston University School of Public Health, Boston, MA, USA. 4. Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 5. University of Iowa, Iowa City, IA, USA. 6. Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA. 7. Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Abstract
OBJECTIVE: There is an interest in identifying a metabolic OA phenotype. We therefore assessed the relation of diabetes and cardiovascular disease to prevalent and incident radiographic (ROA) and symptomatic knee osteoarthritis (SxOA). DESIGN: In two large cohort studies of individuals with or at risk for knee OA, the Multicenter Osteoarthritis Study (MOST) and Osteoarthritis Initiative (OAI), participants self-reported diabetes and cardiovascular disease (CVD) at baseline. We assessed the relation of baseline diabetes and CVD (exposures) to ROA and SxOA cross-sectionally and after 60 (MOST) or 48 (OAI) months of follow-up using logistic regression with GEE to account for 2 knees within an individual, adjusting for potential confounders. RESULTS: In MOST, 6,020 knees of 3,021 participants (60.1% female, mean ± SD age 62.5 ± 8.1, mean BMI 30.7 ± 6.0, 83.3% Caucasian) were included in the analyses. In OAI, 8,645 knees of 4,339 participants (58.2% female, mean ± SD age 61.1 ± 9.2, mean BMI 28.6 ± 4.8, 80.3% Caucasian) were included. We found no significant associations between prevalent diabetes or CVD and prevalent or incident ROA or SxOA. Effect estimates for prevalent ROA and SxOA ranged from 0.80 (95% CI 0.63-1.03) to 1.17 (0.91-1.51). Effect estimates for incident ROA ranged from 0.80 (0.58-1.11) to 0.88 (0.60-1.29) in MOST and from 0.75 (0.50-1.14) to 1.19 (0.81-1.74) in OAI, and for incident SxOA from 0.93 (0.65-1.31) to 1.22 (0.89-1.67) in MOST and from 0.82 (0.59-1.16) to 1.19 (0.85-1.66) in OAI). CONCLUSIONS: Diabetes and CVD were not associated with prevalent or incident knee OA.
OBJECTIVE: There is an interest in identifying a metabolic OA phenotype. We therefore assessed the relation of diabetes and cardiovascular disease to prevalent and incident radiographic (ROA) and symptomatic knee osteoarthritis (SxOA). DESIGN: In two large cohort studies of individuals with or at risk for knee OA, the Multicenter Osteoarthritis Study (MOST) and Osteoarthritis Initiative (OAI), participants self-reported diabetes and cardiovascular disease (CVD) at baseline. We assessed the relation of baseline diabetes and CVD (exposures) to ROA and SxOA cross-sectionally and after 60 (MOST) or 48 (OAI) months of follow-up using logistic regression with GEE to account for 2 knees within an individual, adjusting for potential confounders. RESULTS: In MOST, 6,020 knees of 3,021 participants (60.1% female, mean ± SD age 62.5 ± 8.1, mean BMI 30.7 ± 6.0, 83.3% Caucasian) were included in the analyses. In OAI, 8,645 knees of 4,339 participants (58.2% female, mean ± SD age 61.1 ± 9.2, mean BMI 28.6 ± 4.8, 80.3% Caucasian) were included. We found no significant associations between prevalent diabetes or CVD and prevalent or incident ROA or SxOA. Effect estimates for prevalent ROA and SxOA ranged from 0.80 (95% CI 0.63-1.03) to 1.17 (0.91-1.51). Effect estimates for incident ROA ranged from 0.80 (0.58-1.11) to 0.88 (0.60-1.29) in MOST and from 0.75 (0.50-1.14) to 1.19 (0.81-1.74) in OAI, and for incident SxOA from 0.93 (0.65-1.31) to 1.22 (0.89-1.67) in MOST and from 0.82 (0.59-1.16) to 1.19 (0.85-1.66) in OAI). CONCLUSIONS: Diabetes and CVD were not associated with prevalent or incident knee OA.
Authors: Mia F Williams; Daniel A London; Elaine M Husni; Sankar Navaneethan; Sangeeta R Kashyap Journal: J Diabetes Complications Date: 2016-03-02 Impact factor: 2.852
Authors: Neil A Segal; Michael C Nevitt; K Douglas Gross; Keith D Gross; Jean Hietpas; Natalie A Glass; Cora E Lewis; James C Torner Journal: PM R Date: 2013-08 Impact factor: 2.298
Authors: Ali Mobasheri; Margaret P Rayman; Oreste Gualillo; Jérémie Sellam; Peter van der Kraan; Ursula Fearon Journal: Nat Rev Rheumatol Date: 2017-04-06 Impact factor: 20.543
Authors: Luke P Dawson; Jessica L Fairley; Michelle C Papandony; Sultana Monira Hussain; Flavia M Cicuttini; Anita E Wluka Journal: Semin Arthritis Rheum Date: 2018-02-21 Impact factor: 5.532
Authors: George Hindy; Kristina E Åkesson; Olle Melander; Krishna G Aragam; Mary E Haas; Peter M Nilsson; Umesh T Kadam; Marju Orho-Melander Journal: Arthritis Rheumatol Date: 2019-04-17 Impact factor: 10.995
Authors: Bahram Mohajer; Ali Guermazi; Philip G Conaghan; Francis Berenbaum; Frank W Roemer; Arya Haj-Mirzaian; Clifton O Bingham; Kamyar Moradi; Xu Cao; Mei Wan; Shadpour Demehri Journal: Eur Radiol Date: 2022-01-19 Impact factor: 7.034